Global Newswire by Notified: M&A

NOVEMBER 16, 2023

– Merger to create NASDAQ-listed, commercial-stage AI-Enabled medical technology company focused on bringing FDA-cleared Brain Network Analytics platform to NASDAQ Capital Markets – Merger to create NASDAQ-listed, commercial-stage AI-Enabled medical technology company focused on bringing FDA-cleared Brain Network Analytics platform to NASDAQ Capital (..)

Mergers 66

Mergers Medical Capital Market Capital 66

Focus Investment Banking

JULY 31, 2023

This article focuses on how medical practices are valued by private equity-backed groups, and to an extent, health systems and other strategic acquirers. a physician was out on medical leave) and similar matters. DOWNLOAD FULL ARTICLE The post What is the Value of my Medical Practice?

Medical 52

Medical Private Equity Healthcare Professional Services 52

Tyton Partners

APRIL 10, 2024

Achieve Partners’ social impact focus and deep experience in the digital transformation of education makes them the perfect partner for Elentra to continue to scale its purpose-built platform, and acquire other solutions, to best serve medical and allied health institutions globally.

Education 52

Education Medical Private Equity Equities 52

Tyton Partners

FEBRUARY 3, 2025

K-12 Transaction Spotlight The K-12 education market is undergoing a significant transformation in the post-COVID era, driven by the expiration of federal Elementary and Secondary School Emergency Relief (ESSER) funds.

Education 52

Education Sale Investors Medical 52

Periculum Capital

MAY 14, 2024

Periculum Capital Company, LLC is pleased to announce it has advised Micro-Dyn Medical Systems, Inc., The firm’s primary services include M&A, capital markets, and restructuring advisory, as well as specialized merchant banking services. a leading health care software company, in its acquisition by The Brydon Group.

Sale 52

Sale IT Mergers and Acquisitions Advisory 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40